Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EOG Resources Inc (EOG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

EOG Resources IncTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

EOG Resources Inc vs Zimmer Biomet Holdings Inc — how do they compare? EOG Resources Inc trades at $149.47 (market cap $77.90B), while Zimmer Biomet Holdings Inc trades at $88.99 (market cap $16.95B). The key difference: EOG Resources Inc is far larger — about 4.6× Zimmer Biomet Holdings Inc's market cap, and EOG Resources Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Zimmer Biomet Holdings Inc for 89 Days on average.

EOGZBH
Market Cap
$77.90B$16.95B
Volume
2,930,3862,505,240
Sector
EnergyHealth
52-Week High
$153.74$103.98
52-Week Low
$101.78$79.58
Typical Hold Time
59 Days89 Days
Enterprise Value
$81.24B$24.02B
Dividend Yield
2.75%1.08%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EOG Resources Inc

EOG Resources trades at $144.21, showing minimal daily movement with a slight decline of 0.05%. The stock maintains strong technical momentum with bullish moving averages and sits near pivot point resistance at $145. Fundamentally, EOG demonstrates robust profitability with 25.81% net income margin and attractive valuation metrics including a P/E of 11.56. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $5.07 exceeding expectations. The company maintains solid cash flow generation despite increased capital expenditures.

EOG presents a compelling investment case with strong operational execution, disciplined capital allocation, and shareholder returns through dividends. Analyst consensus remains bullish with 59% buy ratings and $164.77 price target representing 14% upside. Key risks include oil price volatility and execution challenges in maintaining production growth. The combination of value pricing, consistent earnings performance, and positive technical momentum supports a constructive outlook for patient investors.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.

The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EOG

No sentiment data available yet.

ZBH
100% Buy0% Sell
Avg holding period · 89 Days

Top news

Latest headlines on both assets

About EOG Resources Inc

EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.

Read more on EOG →

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH →